OpGen, Inc. engages in developing and deploying precision medicine tools to combat infectious disease in global healthcare settings. It helps physicians enhance patient outcomes by providing information about life-threatening infections and decreasing the spread of infections caused by multidrug-resistant microorganisms. The company offers a portfolio of in vitro diagnostic products and clinical laboratory services that employ molecular diagnostics and bioinformatics. Its QuickFISH products are a suite of FDA-cleared and CE-marked diagnostics used to detect pathogens in positive blood cultures. The company provides Acuitas MDRO gene test to identify the presence of antibiotic resistant genes for high-risk patients quickly and with high sensitivity and specificity; and Acuitas Lighthouse MDRO management system, which offers epidemiological typing, tracking, and trending to inform infection control, surveillance, and antibiotic stewardship decision makers. In addition, it offers Acuitas whole genome sequence analysis for transmission investigations and epidemiology research. OpGen, Inc. has a strategic collaboration with Hitachi High-Technologies Corporation to commercialize its genome mapping technology for mapping, assembly, and analysis of human DNA. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
http://www.priceseries.com/trade/OPGN-OpGen-Inc-stock-gains-28-percent-a-Trade-Record-by-priceSeries-2021020220210219.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments